

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076928 A1

(51) International Patent Classification⁷: **G01N 33/48**

(21) International Application Number: **PCT/US03/07103**

(22) International Filing Date: **7 March 2003 (07.03.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/362,087 7 March 2002 (07.03.2002) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US];**
615 Arapen Drive, Suite 110, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SZABO, Aniko [HU/US];** 2192 Rolling Oaks Lane, Layton, UT 84040 (US). **BOUCHER, Kenneth [US/US];** 421 Center Street, Salt Lake City, UT 84103 (US). **JONES, David [US/US];** 1780 E. Logan Avenue, Salt Lake City, UT 84108 (US). **KLEBANOV, Lev [RU/RU];** Solidarnosti, 13-2-132, St. Petersburg, 193312 (RU). **TSODIKOV, Alexander [RU/US];** 5562 Brookridge Drive, 14j, Salt Lake City, UT 84107 (US). **YAKOVLEV, Andrei [RU/US];** 6204 S. Rodeo Lane, Salt Lake City, UT 84121 (US).

(74) Agents: **BOOTH, Paul, M. et al.;** Heller Ehrman White & McAuliffe LLP, 1666 K Street, N.W., Suite 300, Washington, DC 20006-1228 (US).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)**

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **METHODS FOR IDENTIFYING LARGE SUBSETS OF DIFFERENTIALLY EXPRESSED GENES BASED ON MULTIVARIATE MICROARRAY DATA ANALYSIS**

(57) Abstract: The present invention provides multivariate methods for identifying differentially expressed genes based on microarray expression data. An improved random search procedure involving certain probability distances is provided. The methods of this invention implement a successive elimination procedure to remove smaller subsets resulted from each step of the random search thereby establishing a larger set of differentially expressed genes.



WO 03/076928 A1

METHODS FOR IDENTIFYING LARGE SUBSETS OF DIFFERENTIALLY EXPRESSED GENES BASED ON MULTIVARIATE MICROARRAY DATA ANALYSIS

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates in general to statistical analysis of microarray data generated from nucleotide arrays. Specifically, the present invention relates to identification of differentially expressed genes by multivariate microarray data analysis. More specifically, the present invention provides an improved multivariate random search method for identifying large sets of genes that are differentially expressed under a given biological state or at a given biological locale of interest according to the values of a probability distance calculated for numerous subsets of genes. The method of the invention provides a successive elimination procedure to remove smaller subsets resulted from each step of the random search thereby establishing a larger set of differentially expressed genes.

DESCRIPTION OF THE RELATED ART

Gene expression analyses based on microarray data promises to open new avenues for researchers to unravel the functions and interactions of genes in various biological pathways and, ultimately, to uncover the mechanisms of life in diversified species. A significant objective in such expression analyses is to identify genes that are differentially expressed in different cells, tissues, organs of interest or at different biological states. So identified, a set of differentially expressed genes associated with a certain biological state, e.g.,

tumor or certain pathology, may point to the cause of such tumor or pathology, and thereby shed light on the search of potential cures.

In practice, however, gene expression studies are hampered by many difficulties. For example, poor reproducibility in microarray readings can obscure actual differences between normal and pathological cells or create false positives and false negatives. The tension between the extremely large number of genes present (hence high dimensionality of the feature space) and the relatively small number of measurements also poses serious challenges to researchers in making accurate diagnostic inferences.

Existing methods for selecting differentially expressed genes are typically univariate, not taking into account the information on interactions among genes. As appreciated by an ordinary skilled molecular biologist, genes do not operate in isolation - activation of one gene may trigger changes in the expression levels of other genes. That is, genes may be involved in one or more pathways or networks. Therefore, determination of differentially expressed genes calls for consideration of covariance structure of the microarray data, in addition to, for example, mean expression levels. In this regard, however, application of well-established statistical techniques for multidimensional variable selection encounters much difficulty. This is so because, in one aspect, the small number of independent samples and the presence of outliers make the estimates on selected variables unstable for large dimensions. In other words, only small sets of genes can be meaningfully considered while a relatively large number of genes are potentially differentially expressed. It is generally impossible to compare all gene subsets and find the optimal one because the number of possible gene combinations is prohibitively large. On the other hand, if a global optimum could be found, it might be overly specific to a training sample due to overfitting. Thus, it remains a significant challenge to scale methods for identifying differentially expressed genes to deal with microarray data of high dimensional space.

Therefore, there is a need to address the difficulties in applying multivariate analysis to microarray data - a need to provide methods for identifying differentially expressed genes based on gene expression data with high dimensional feature space.

5 SUMMARY OF THE INVENTION

It is therefore an object of this invention to provide multivariate methods for analyzing microarray gene expression data of high dimensional space thereby identifying differentially expressed genes. Particularly, it is an object of this invention to provide methods for identifying larger sets of differentially expressed genes by successive eliminating smaller subsets of genes identified from each step of the random search procedure.

In accordance with the present invention, there is provided methods for identifying a set of genes from a multiplicity of genes whose expression levels at a first and a second state, in a first and a second tissue, or in a first and a second types of cells are measured in replicates using one or more nucleotide arrays, thereby generating a first plurality of independent measurements of the expression levels for the first state, tissue, or type of cells and a second plurality of independent measurements of the expression levels for the second state, tissue, or type of cells. The methods comprise: (a) identifying a quality function capable of evaluating the distinctiveness between the first plurality and the second plurality; (b) forming a first predetermined number of permutations from the first and the second pluralities, dividing the permutations into a first permuted plurality and a second permuted plurality, corresponding in size, to the first and second plurality, respectively, and identifying groups of genes the size of which is a second predetermined number, wherein the values of the quality function for the group of genes in the first permuted and second permuted pluralities attain the maximum; (c) determining, from the first and second permuted pluralities, the top α^{th}

percentile of the null distribution based on a quantitative characteristic of the groups of genes; (d) identifying, based on the first and second pluralities, a subset of genes the size of which is the second predetermined number, wherein the values of the quality function for the subset of genes in the first and second pluralities attain the maximum; (e) adding to the set of genes, the subset, if the value of the quantitative characteristic associated with the subset exceeds the top α^{th} percentile of the null distribution; and (f) removing from the first and second pluralities, all measurements on the subset, if the maximum value of the quality function associated with the subset exceeds the top α^{th} percentile of the null distribution, and repeating steps (d)-(f) until no more measurements are left in the first and second pluralities or the value of the quantitative characteristic associated with the subset does not exceed the top α^{th} percentile of the null distribution.

According to the present invention, in certain embodiments, the states may be biological states, physiological states, pathological states, and prognostic states. In other embodiments, the tissues may be normal lung tissues, cancer lung tissues, normal heart tissues, pathological heart tissues, normal and abnormal colon tissues, normal and abnormal renal tissues, normal and abnormal prostate tissues, and normal and abnormal breast tissues. In yet other embodiments, the types of cells may be normal lung cells, cancer lung cells, normal heart cells, pathological heart cells, normal and abnormal colon cells, normal and abnormal renal cells, normal and abnormal prostate cells, and normal and abnormal breast cells. In still other embodiments, the types of cells may be cultured cells and cells isolated from an organism.

In one embodiment of this invention, the quality function is represented by a probability distance between random vectors. In another embodiment, the probability distance function is selected from the group consisting of the Mahalanobis distance and the Bhattacharya distance. In yet another embodiment, the probability distance function is defined as:

$$N(\mu, \nu) = 2 \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\mu(x) d\nu(y) - \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\mu(x) d\mu(y) - \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\nu(x) d\nu(y)$$

where μ and ν are two probability measures defined on the Euclidean space, and $L(x,y)$ is a strictly negative definite kernel. In still another embodiment, the negative definite kernel is combined with the Euclidean distance between x and y to form a composite kernel function.

5 According to one embodiment, the quantitative characteristic is selected from the group consisting of an associated probability distance, a test set classification rate, and a cross-validation classification rate.

 According to another embodiment, the formation of the permutations further comprises: (i) shifting the measurements in the first and second
10 pluralities such that the marginal means thereof share the same true mean; and (ii) randomly permuting the resulting shifted measurements thereby forming a null-distribution of permutations.

 According to yet another embodiment, the identifying further comprises:
(i) calculating the values of the quality function for the subset of genes in the
15 first and second pluralities thereby evaluating the distinctiveness of the first and second pluralities; and (ii) substituting a gene in the subset with one outside of the subset, thereby generating a new subset, and repeating step (i), keeping the new subset if the distinctiveness increases and the original subset if otherwise; and (iii) repeating steps (i) and (ii) for a fourth predetermined
20 number of times.

 According to still another embodiment, the identifying further comprises: (i) randomly dividing the first and the second pluralities into v groups of an approximate equal size; (ii) removing one of the v groups from the first and second pluralities and identifying, from the resulting reduced first and
25 second pluralities, a subset of genes for which the value of the quality function attains the maximum; and (iii) repeating step (ii) for each of the v groups thereby obtaining v subsets of genes.

In various embodiments of the invention, the nucleotide arrays may be arrays having spotted thereon cDNA sequences and/or arrays having synthesized thereon oligonucleotides.

BRIEF DESCRIPTION OF DRAWINGS

5

Fig. 1 shows the properties of the optimal subsets of genes identified in a computer simulation study using a random search method with a successive elimination procedure according to one embodiment of the invention.

10 Fig. 2 shows the properties of the optimal subsets of genes identified in an expression analysis of colon cancer cells using a random search procedure with a successive elimination procedure according to one embodiment of the invention.

15 Fig. 3 shows the estimates of the null-distributions based on the associated probability distance (the top panel), the test set classification rate (the bottom panel, the curve on the left), and the cross validation classification rate (the bottom panel, the curve on the right) for the 5-element optimal subset of genes in a "no-difference" dataset generated by a resampling procedure according to one embodiment of the invention.

DETAIL DESCRIPTIONS OF DISCLOSURE

20 **Definition**

As used herein, the term "microarray" refers to nucleotide arrays; "array," "slide," and "chip" are used interchangeably in this disclosure. Various kinds of nucleotide arrays are made in research and manufacturing facilities worldwide, some of which are available commercially. There are, for
25 example, two kinds of arrays depending on the ways in which the nucleic acid materials are spotted onto the array substrate: oligonucleotide arrays and cDNA arrays. One of the most widely used oligonucleotide arrays is GeneChipTM

made by Affymetrix, Inc. The oligonucleotide probes that are 20- or 25-base long are synthesized in silico on the array substrate. These arrays tend to achieve high densities (e.g., more than 40,000 genes per cm²). The cDNA arrays, on the other hand, tend to have lower densities, but the cDNA probes are typically much longer than 20- or 25-mers. A representative of cDNA arrays is LifeArray made by Incyte Genomics. Pre-synthesized and amplified cDNA sequences are attached to the substrate of these kinds of arrays.

Microarray data, as used herein, encompasses any data generated using various nucleotide arrays, including but not limited to those described above. Typically, microarray data includes collections of gene expression levels measured using nucleotide arrays on biological samples of different biological states and origins. The methods of the present invention may be employed to analyze any microarray data; irrespective of the particular microarray platform from which the data are generated.

Gene expression, as used herein, refers to the transcription of DNA sequences, which encode certain proteins or regulatory functions, into RNA molecules. The expression level of a given gene refers to the amount of RNA transcribed therefrom measured on a relevant or absolute quantitative scale. The measurement can be, for example, an optic density value of a fluorescent or radioactive signal, on a blot or a microarray image. Differential expression, as used herein, means that the expression levels of certain genes are different in different states, tissues, or type of cells, according to a predetermined standard. Such standard maybe determined based on the context of the expression experiments, the biological properties of the genes under study, and/or certain statistical significance criteria.

The terms "vector," "probability distance," "distance," "the Mahalanobis distance," "the Euclidean distance," "feature," "feature space," "dimension," "space," "type I error," "type II error," "ROC curve," "permutation," "random permutation," and "null distribution" are to be

understood consistently with their typical meanings established in the relevant art, i.e. the art of mathematics, statistics, and any area related thereto. For example, a set of microarray data on p distinct genes represents a random vector $X = X_1, \dots, X_p$ with mutually dependent components.

5 ***Random Search to Identify Subsets of Genes of a Predetermined Size***

Suppose two tissues, types of cells, or biological states are of interest, one of which corresponds to the normal physiology while the other implicates certain pathology such as tumor. The distinctiveness of these two tissues, types
 10 of cells, or states can be evaluated by microarray experiments in which the expression levels of all the genes (up to thousands measured on a single chip or slide as made possible by the recent advances in the microarray manufacturing) are determined. A collection of differentially expressed genes would therefore account, at the genomic/genetic level, for the distinctiveness of the two tissues,
 15 type of cells, or states. Certain multivariate distances are employed to evaluate such distinctiveness according to this invention.

For example, a probability distance and its nonparametric estimate may be used in this context. Let μ and ν be two probability measures defined on the Euclidean space. Let $L(x,y)$ be a strictly negative definite kernel, that is

20 $\sum_{i,j=1}^s L(x_i, x_j) h_i h_j \leq 0$ for any x_1, \dots, x_s and h_1, \dots, h_s , $\sum_{i=1}^s h_i = 0$ with equality if and only if all $h_i = 0$. It can be shown that a probability distance $N(\mu, \nu)$ as defined below is a metric in the space of all probability measures on \mathbb{R}^d .

$$N(\mu, \nu) = 2 \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\mu(x) d\nu(y) - \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\mu(x) d\mu(y) - \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\nu(x) d\nu(y)$$

25 Consider two independent samples, consisting of n_1 and n_2 observations respectively, represented by the d -dimensional vectors x_1, \dots, x_{n_1} and y_1, \dots, y_{n_2} . An empirical counterpart of $N(\mu, \nu)$ may be represented as follows

$$\hat{N} = N(\mu_{n_1}, \nu_{n_2}) = \frac{1}{n_1 n_2} \sum_{i=1}^{n_1} \sum_{j=1}^{n_2} 2L(x_i, y_j) - \frac{1}{n_1^2} \sum_{i=1}^{n_1} \sum_{j=1}^{n_1} L(x_i, x_j) - \frac{1}{n_2^2} \sum_{i=1}^{n_2} \sum_{j=1}^{n_2} L(y_i, y_j).$$

A pertinent kernel function L needs to be chosen when the probability distance $N(\mu, \nu)$ is used. Appropriate choices include the Euclidean distance between ranks and a monotone function of the Euclidean distance satisfying the condition of negative definiteness. Additionally, an alternative class of kernel functions may be used to measure pairwise gene interaction.

Let \mathbf{x} and \mathbf{y} denote observations in two samples on a gene set and \mathbf{x}^r and \mathbf{y}^r denote the corresponding rank-adjusted observations. Consider either of these observations to be points in Euclidean space. Let S be a measurable subset of \mathbb{R}^d . Define L_S by the rule $L_S(\mathbf{x}, \mathbf{y}) = 0$ if both $\mathbf{x} \in S$ and $\mathbf{y} \in S$ and $L_S(\mathbf{x}, \mathbf{y}) = 1$ otherwise. L_S is a negative definite kernel. Suppose, $\mathbf{x}_i \in S$, $1 \leq i \leq r$, and $\mathbf{x}_i \notin S$, $r+1 \leq i \leq s$, then one would have

$$\sum_{i,j=1}^s (1 - L_S(\mathbf{x}_i, \mathbf{y}_j)) h_i h_j = \sum_{i,j=1}^r h_i h_j = \left(\sum_{i,j=1}^r h_i \right)^2 \geq 0.$$
 Thus $(1 - L_S)$ is a positive definite kernel.

More generally, let $f(\mathbf{x})$ be a function from a space to the interval $[0,1]$, and define $L_f(\mathbf{x}, \mathbf{y}) = \max(f(\mathbf{x}), f(\mathbf{y}))$, then L_f is a negative definite kernel. Also, if one defines $g_a(\mathbf{x}, \mathbf{y}) = 0$ provides both $f(\mathbf{x}) > a$ and $f(\mathbf{y}) > a$ and $g_a(\mathbf{x}, \mathbf{y}) = 1$ otherwise, then, from the previous paragraph, g_a is a negative definite kernel. It follows from the equality $L_f(\mathbf{x}, \mathbf{y}) = \int_0^1 g_a(\mathbf{x}, \mathbf{y}) da$ that L_f is negative definite. Since a negative definite kernel is unaffected by an arbitrary additive shift, it is clear that $L_f(\mathbf{x}, \mathbf{y}) = \max(f(\mathbf{x}), f(\mathbf{y}))$ will be a negative definite kernel for any bounded function f .

If w_i are positive weights and f_i , $1 \leq i \leq d$, are functions from to $[0,1]$, then $L = \sum_{i=1}^d w_i L_{f_i}$ is also a negative definite kernel. From the foregoing derivations, one would also have: if $\{f_i\}$ separates points, that is, $f_i(\mathbf{x}) = f_i(\mathbf{y})$ for all i implies $\mathbf{x} = \mathbf{y}$, then L is strictly negative definite.

Negative definite kernels of the type described above may be combined with the usual Euclidean distance to form composite kernel functions. For

example, define a region function $R_q(u,v)=q\lfloor qu\rfloor + \lfloor qv\rfloor$ (here $\lfloor \cdot \rfloor$ denotes the floor function, its value is the largest integer not exceeding the argument and $q \geq 2$ is an integer parameter). This function is constant on each of the q^2 obtained by dividing the sides of the $(0,1)^2$ into q equal segments. Then the following kernels on the ranked data may be defined:

$$L_1(\mathbf{x}^r, \mathbf{y}^r) = \sqrt{\sum_{g \in S} (x_g^r - y_g^r)^2},$$

$$L_2(\mathbf{x}^r, \mathbf{y}^r) = w_1 L_1(\mathbf{x}^r, \mathbf{y}^r) + w_2 \sum_{(g_1, g_2) \in S^2} \left(1 - I\{R_q(x_{g_1}^r, x_{g_2}^r) = R_q(y_{g_1}^r, y_{g_2}^r)\} \right),$$

where I is the indicator function. Then L_1 is the standard Euclidean distance and L_2 falls into the class described above. We choose the weights w_1 and w_2 to

balance the two components of L_2 with respect to their maximum values:

$$w_1 = 1/d_{max} \text{ and } w_2 = 1/\binom{d_{max}}{2}, \text{ where } d_{max} \text{ is the maximum subset dimension}$$

under consideration. The second component of the kernel will be insensitive to perturbation, yet pick up sets of genes that have similar expression levels across samples in one tissue and different expression patterns in the two tissues.

In another alternative embodiment, a function L_f is based on the correlation coefficient. Let \mathbf{x}^n and \mathbf{y}^n denote normalized data such that the tissue-specific sample mean and variance are zero and one respectively. For each pair of genes g_1 and g_2 , consider the function $f_{g_1, g_2}(\mathbf{x}^n) = x_{g_1}^n x_{g_2}^n$. The corresponding negative definite kernel L_{g_1, g_2} will detect differences in correlation between the two tissues. For example, if the expressions of g_1 and g_2 have correlation coefficient ρ in one tissue and are uncorrelated in the other, it follows from $2 \max(\rho, 0) - \max(\rho, \rho) - \max(0, 0) = |\rho|$ that the corresponding distance between the tissues will be approximately equal to $|\rho|$.

A negative definite kernel may, in this embodiment, be defined as:

$$L_3(x, y) = w_1 L_1(x, y) + w_2 \sum_{(g_1, g_2) \in S^2} L_{g_1, g_2}(x, y)$$

The weights w_1 and w_2 may be chosen to balance the contribution of the two components. A distance based on L_3 will tend to pick up sets of genes with separated means and differences in correlation in the two samples.

5 In various embodiments of this invention, once an aforementioned multivariate distance is selected, it may be used to search for a subset(s) of genes that are differentially expressed between the two tissues, types of cells, or biological states as the corresponding values of the distance are maximized. The size of such subsets is predetermined, which are typically small since they
10 are limited by the available sample replicates. In theory, all subsets of a predetermined size need to be evaluated in terms of the adopted distance and the one that provides a maximum distance should be chosen as the final set of differentially expressed genes. In practice, however, the number of possible subsets exponentially increases with the total number of genes involved and,
15 consequently, the exhaustive search procedures as well as the branch-and-bound method (see, e.g., Fukunaga K., (1990), Introduction to Statistical Pattern Recognition, Academic Press, London, 2nd.) become computationally prohibitive. Therefore, various stepwise random search procedures may be advantageously adopted according to this invention in identifying subsets of
20 differentially expressed genes of a predetermined size.

In this connection, the search for a subset of genes with the best discrimination between two tissues, type of cells, or states often turns up overly-optimistic conclusions due to overfitting, i.e., finding overly specific patterns that do not extend to new samples. To mitigate such local selection
25 bias, cross validation techniques may be adopted in random searches according to this invention, an example procedure (Procedure 1) is provided as follows:

1. Randomly divide the data into v groups of an approximate equal size;

2. Drop one of the n groups and find the optimal subset of genes using only the data from $v-1$ group, based on the evaluation of the applicable probability distance.

3. Repeat step 2 in succession for each of the groups, obtaining v optimal subsets.

4. Combine these sets by selecting the genes with the highest frequencies of occurrences.

In alternative embodiments, multiple local searches may be performed and then the resulting locally sub-optimal subsets may be integrated such that a final set of differentially expressed genes may be identified (e.g., by including the genes with the highest frequency of occurrences in the locally sub-optimal subsets).

Establishing Larger Sets of Genes Based on the Identified Smaller Subsets

As discussed above, random search procedures based on certain probability distances may be utilized to identify a subset of differentially expressed genes of a predetermined size. And, since a predetermined size as such often is limited by the scarcity of the sample size (especially when the total number of genes is large and the dimensionality of the microarray data is high), it is desirable to find a way to enlarge the size of the set of differentially expressed genes identified.

In one embodiment of this invention, a successive selection procedure is adopted to eliminate groups of genes after each run of the random search procedure, until no more subsets of genes can be found that satisfy the search criteria. The final set of differentially expressed genes would then include all the removed genes at each step. Essential to this method is the formulation of a stopping rule at each step.

The formulation of such an appropriate stopping rule turns on the evaluation of the properties of an optimal set of genes in a "no-difference" data set. Various quality functions may be used in this context to provide a model to evaluate such properties. For example, certain multivariate distances are used as the quality function in various embodiment of this invention. The selection process based on the application of such multivariate quality functions would necessarily be influenced by the covariance structure of the microarray data. Thus, the "no-difference" baseline data (i.e., corresponding to the null-distribution) ought to be generated in such a way that the covariance data structure is preserved. The following two-step "resampling" process (Procedure 2) meets such requirement. The first step ensures that the marginal means of the two data sets (may have been obtained from two tissues, types of cells, or biological states) have the same true mean. And, the second step mimics the biological variability through permutation.

Denote the adjusted fluorescence level for gene i , $i=1, \dots, p$ in the two tissues by X_{ij} , $j=1, \dots, n_1$ and Y_{ij} , $j=1, \dots, n_2$, respectively.

1. For each gene i , $i=1, \dots, p$ shift the values from the two data sets so they are centered at the overall mean for this gene, that is

$$X_{ij}^* = X_{ij} - \bar{X}_i + \frac{n_1 \bar{X}_i + n_2 \bar{Y}_i}{n_1 + n_2}, \quad Y_{ij}^* = Y_{ij} - \bar{Y}_i + \frac{n_1 \bar{X}_i + n_2 \bar{Y}_i}{n_1 + n_2}$$

2. Randomly permute the resulting n_1+n_2 vectors. The first n_1 and the last n_2 vectors provide a random sample from the null-distribution.

Based on this permutation resampling scheme, the null-distributions of various quantitative characteristics of the optimal gene set may be estimated. For example, the associated probability distance, cross validation classification rate (using a selected subset upon cross validation), and test set classification rate (using an independent test set) may be considered. A test set classification rate is calculated by classifying each sample from an independent test set using

the selected subset of genes and the entire training set and determining the rate of the correct classification. A cross-validation classification rate is calculated by classifying each sample in the training set (in the absence of a test set) using the selected subset of genes and the rest of the training set and determining the rate of the correct classification. Generally, the test set classification rate may be most desirable but, due to the scarcity of samples, an appropriate test set is often unavailable. In such situations, the between-tissue distance associated with gene sets may be a good and stable proxy for the classification rate.

According to a particular embodiment, a probability distance-based successive-selection procedure is adopted in selecting a subset of genes that are differentially expressed in two tissues, type of cells, or biological states, as outlined below (Procedure 3). The successive selection based on cross-validation or test set classification rates may be similarly adopted in connection with random searches in alternative embodiments of this invention.

The following procedure (Procedure 3) starts with the selection of a subset of genes with a size k and requires a significance level α for defining a percentile of the null-distribution of the data sets.

1. Form m independent permutation samples of sizes n_1 and n_2 , respectively, from n_1+n_2 observations (arrays/slides). For each of the permutation samples, find an optimal k -element subset of genes for which the associated probability distance attains its maximum. Estimate from the permutation samples the top α^{th} percentile D_α of the baseline distribution of the optimal distance (referred to as the null-distribution).

2. Returning to the original two data set setting, find the k -element optimal set of genes for which the associated probability distance attains its maximum and denote it by G_I . If the associated probability distance $D(G_I) > D_\alpha$, then continue, otherwise stop the search.

3. In the t^{th} iteration, discard sets G_1, \dots, G_{t-1} and find the k -element optimal set G_t from the remaining genes. If the associated distance $D(G_t) > D_{\alpha}$, then continue with this step (next iteration), otherwise proceed to step 4.

4. The final set of differentially expressed genes are defined by the
5 union $\bigcup_{j=1}^t G_j$.

Computer Simulation of the Improved Random Search

A simulation study was performed to evaluate the improved random search method with the successive elimination procedure. A total of 1000
10 genes was divided into subsets of equal size 20. In the first data set, no differential expression was imposed, and hence any difference shown would be due to the within-tissue "biological variability." In the second data set, one of the subsets (including 20 mutually dependent expression signals) was set to be differentially expressed with a ratio of two. The correlation structure was kept
15 the same in the two data sets. Further, an independent test set of 100 observations (with equal proportions of the two hypothetical tissues) was simulated for the two data sets in order to estimate the true classification rate of the selected gene sets.

A cross-validated random search was performed in accordance with
20 Procedure 1 supra. Particularly, step 2 of Procedure 1 was carried out in the following details (Procedure 4):

1. Randomly select k genes to form the initial approximation; calculate the associated probability distance between the two data sets for this subset of genes.
- 25 2. Replace at random one gene from the current subset with a gene outside of the subset and calculate the value of the associated probability distance for the resulting new subset; if the distance is larger than that of the

previous subset, keep the new subset and, otherwise, revert to the previous subset.

3. Repeat the process until a predetermined number M of iterations is reached.

5 In this particular simulation, M was set at 100,000. The successive search for 5-member optimal gene sets ($k=5$) was performed using the 10-fold ($v=10$) cross-validated search procedure (Procedure 1). The Euclidean distance was chosen for the kernel $L(x, y)$ in the distance measure. For each of the successive optimal sets G_i , the corresponding optimal distance was recorded
10 and the tissue classification rate was estimated using both cross validation (using the selected gene set) and the independent test set. The results are shown in Fig. 1.

Referring to Fig. 1, the top panel shows the results for the data set that had no difference imposed whereas the bottom panel shows the results for the
15 data set that had a subset of 20 genes to be differentially expressed in the two hypothetical tissues. In both panels, the left y axis represents the associated probability distance while the right y axis denotes the classification rate based on the independent test set (hence test set classification rate - "Class") and the classification rate based on cross validation using selected gene set (hence
20 cross validation classification rate - "CV"). The x axis of both panel denotes the number of subsets of genes with a predetermined size of 5. As shown in both panels of Fig. 1, the estimate of the test set classification rate and that of the cross validation classification rate are both highly variable for both data sets, whereas the associated distance (Dist) is decreasing monotonically. Since
25 the optimal sets were selected based on the associated probability distance in this simulation, the observed monotonicity confirms the ability of the random search procedure of this invention to find an optimal subset.

To reduce the observed variability of the classification rate estimates, isotonic regression (see, Robertson T. et al., (1988) Order Restricted Statistical

Inference, Wiley, London) was performed to smooth the corresponding curves and thereby generate the corresponding solid lines in Fig. 1, assuming the true rates to be non-increasing. The dotted horizontal lines represent the level of the 99th percentile of the null-distributions of the corresponding measures (i.e., the associated probability distance, the test set classification rate, and the cross validation classification rate); they were estimated by generating 100 random permutation samples that mimic "no-difference" data in accordance with Procedure 2 supra. For the first data set, referring to the top panel of Fig. 1, all the observed curves lie entirely below their cutoff values, which demonstrates that the random search of the invention with the successive elimination procedure correctly identifies no differentially expressed genes in the first data set.

For the second data set, since 20 genes were set to be differentially expressed, the selection should stop after 4 iterations (i.e., to identify 4 subsets of 5 genes). Referring to the bottom panel of Fig. 1, the distance curve (Dist) passes its cutoff level after the third iteration, whereas the cross validation and the test set classification curves pass their cutoff levels after the fourth iteration. Thus, in the simulated random search, the successive elimination procedures based on associated distance, the test set classification rate, as well as the cross validation classification rate all performed satisfactorily in this simulation, with the distance-based procedure slightly inferior to the other two as it stopped early. However, the distance-based procedure demonstrated superior stability and therefore it remains a powerful alternative in certain embodiments of this invention. In summary, the distance based cutoff identified $14/20=70\%$ of the 20 differentially expressed genes with a false positive (type I error) rate of only $1/15=6.7\%$, while the two classification based cutoffs identified $16/20=80\%$ of the differentially expressed genes with a $4/20=20\%$ false positive rate. The differentially expressed genes were marked with stars in the bottom panel of Fig 1.

The invention is further described by the following examples, which are illustrative of the invention but do not limit the invention in any manner.

Example 1: a Source Code Segment Implementing Successive Selection and Re-sampling

```

5  unit FExclude;

    interface

10  uses
    Windows, Messages, SysUtils, Classes, Graphics, Controls, Forms, Dialogs,
    Spin, StdCtrls, Grids, Algrid, EnhCBox, NumIO, ComCtrls, Matrix,
    Vector;

15  type
    TExcludeForm = class(TForm)
        NExcludeSteps: TSpinEdit;
        Label1: TLabel;
        RunEliminationButton: TButton;
20  ExcludeResult: TStringAlignGrid;
        SaveButton: TButton;
        SaveDialog: TSaveDialog;
        Label2: TLabel;
        Class1Box: TEnhComboBox;
25  Class2Box: TEnhComboBox;
        H0Button: TButton;
        H0replInput: TNumIO;
        Label3: TLabel;
        ExcludePB: TProgressBar;
30  RandomClusterButton: TButton;
        RunFromDiffClButton: TButton;
        procedure RunEliminationButtonClick(Sender: TObject);
        procedure FormCreate(Sender: TObject);
        procedure SaveButtonClick(Sender: TObject);
35  procedure ExcludeResultKeyDown(Sender: TObject; var Key: Word;
        Shift: TShiftState);
        procedure ExcludeResultFixedRowClick(Sender: TObject; row: Integer);
        procedure ClassBoxDblClick(Sender: TObject);
        procedure H0ButtonClick(Sender: TObject);
40  procedure RandomClusterButtonClick(Sender: TObject);
        procedure RunFromDiffClButtonClick(Sender: TObject);
    private
        { Private declarations }
        procedure OneEliminationStep;
45  function ClassifyTestSets(filename: string; normal, centerdata: boolean)
        : string;
    public
        { Public declarations }
        PermMat1, PermMat2: TMatrix;
50  RandDistCurves, ClassCurves, RandCV: TMatrix;
        MeanDiff: TVector;
    end;

    var
55  ExcludeForm: TExcludeForm;

```

implementation

uses FDiffClust, DiffCluster, ClassificationF, readdata, RandomGen;

```

5  {$R *.DFM}

procedure TExcludeForm.RunEliminationButtonClick(Sender: TObject);
var i, nsteps: integer;
    testset: boolean;
10  begin
    nsteps:= NExcludeSteps.Value;
    ExcludeResult.RowCount:= nsteps+1;
    testset:= (FileExists(Class1Box.Text)) and
              (FileExists(Class2Box.Text));
15  ExcludePB.Position:= 0;
    ExcludePB.max:= nsteps + 1;
    for i:= 1 to nsteps do begin
        try
            ExcludePB.StepIt;
20            ExcludePB.Update;
            BatchProcess:= True;
            DiffClusterForm.FindDiffClusterButtonClick(self);
            DiffClusterForm.DistButtonClick(self);
            if not Assigned(ClassificationForm) then
25                ClassificationForm:= TClassificationForm.Create(self);
            if DiffClusterForm.AdjustType.ItemIndex <=2 then
                ClassificationForm.AdjustOptions.ItemIndex:=
                    DiffClusterForm.AdjustType.ItemIndex;
            ClassificationForm.CrossvalidButtonClick(self);
30            ExcludeResult.Row:= i;
            ExcludeResult.CellAsInt[0,i]:= i;
            ExcludeResult.Cells[1,i]:= DiffClusterForm.OutputMemo.Text;
            ExcludeResult.Cells[2,i]:= ClassificationForm.PCorrectOutput.Text+'%';
            ExcludeResult.Cells[3,i]:= DiffClusterForm.DistOutput.Caption;
35            ExcludeResult.Cells[4,i]:=
                FloatToStrF(MinFreqInDiffcl*100,ffFixed,3,1)+'%';
            ExcludeResult.Cells[5,i]:=
                FloatToStrF(MaxFreqInDiffcl*100,ffFixed,3,1)+'%';
            if testset then begin
40                ExcludeResult.Cells[6,i]:=
                    ClassifyTestSets(Class1Box.Text,True,False)+'%';
                ExcludeResult.Cells[7,i]:=
                    ClassifyTestSets(Class2Box.Text,False,False)+'%';
            end;
45            OneEliminationStep;
        finally
            BatchProcess:= False;
        end;
    end;
50    ExcludePB.Position:= 0;
end;

procedure TExcludeForm.OneEliminationStep;
var i, gene: integer;
55    genelist: TStringList;
begin
    genelist:= TStringList.Create;
    try
        genelist.CommaText:= DiffClusterForm.OutputMemo.Text;
60        for i:= 0 to genelist.Count-1 do begin

```

```

        gene:= StrToInt(genelist[i]);
        UseGeneInd[gene-1]:= 0;
    end;
    finally
5      genelist.Free;
    end;
end;

function TExcludeForm.ClassifyTestSets;
10 begin
    with ClassificationForm do begin
        ClassifFileName.Text:= filename;
        if centerdata then
            RunButtonClick(H0Button)
15        else
            RunButtonClick(RunEliminationButton);
        if normal then
            ActualClassOptions.ItemIndex:= 0
        else
20        ActualClassOptions.ItemIndex:= 1;
        Result:= PCorrectOutput.Text;
    end;
end;

25 procedure TExcludeForm.FormCreate(Sender: TObject);
begin
    ExcludeResult.AllowCutnPaste:= True;
    ExcludeResult.PasteEditableOnly:= False;
end;

30 procedure TExcludeForm.SaveButtonClick(Sender: TObject);
begin
    if SaveDialog.Execute then
        ExcludeResult.SaveToFile(SaveDialog.FileName);
35 end;

procedure TExcludeForm.ExcludeResultKeyDown(Sender: TObject; var Key: Word;
Shift: TShiftState);
begin
40     if (Key=67) then
        if (Shift=[ssCtrl]) then
            with ExcludeResult do
                Contents2CSVClipboard(#9,Selection);
end;

45 procedure TExcludeForm.ExcludeResultFixedRowClick(Sender: TObject;
row: Integer);
begin
    if ExcludeResult.Cells[1,row]<>" then
50     with DiffClusterForm do begin
        OutputMemo.Clear;
        OutputMemo.Text:=ExcludeResult.Cells[1,row];
    end;
end;

55 procedure TExcludeForm.ClassBoxDb1Click(Sender: TObject);
begin
    if SaveDialog.Execute then begin
        (Sender as TEnhComboBox).Text:= SaveDialog.FileName;
60 end;
end;

```

end;

procedure TExcludeForm.H0ButtonClick(Sender: TObject);

var A, B: TMatrix;

```

5   ss1, ss2, s, i, j, k, nH0rep, nsteps: integer;
   sampleperm: array of double;
   stepmin, stepmax: double;
   testset: boolean;
begin
10  case DiffClusterForm.AdjustType.ItemIndex of
    0: begin A:= normal; B:= polyp end;
    1: begin A:= renormal; B:= repolyp end;
    2: begin A:= rnormal; B:= rpolyp end;
    else Exit;
15  end;
   testset:= (FileExists(Class1Box.Text)) and
             (FileExists(Class2Box.Text));
   ss1:= A.NrOfRows;
   ss2:= B.NrOfRows;
20  SetLength(sampleperm, ss1+ss2);
   for i:= 1 to ss1 do
     sampleperm[i-1]:= i;
   for i:= 1 to ss2 do
     sampleperm[ss1+i-1]:= ss1+i;
25  PermMat1:= TMatrix.Create(A.NrOfColumns, ss1);
   PermMat2:= TMatrix.Create(B.NrOfColumns, ss2);
   nH0rep:= Trunc(H0repInput.Value);
   nsteps:= NExcludeSteps.Value;
   RandDistCurves:= TMatrix.Create(nH0rep, nsteps);
30  RandCV:= TMatrix.Create(nH0rep, nsteps);
   if not Assigned(ClassificationForm) then
     ClassificationForm:= TClassificationForm.Create(self);
   if testset then begin
     ClassCurves:= TMatrix.Create(nH0rep, nsteps);
35  end;
   //calculate vector of gene-mean differences
   MeanDiff:= TVector.Create(lines);
   for i:= 1 to lines do
     MeanDiff[i]:= B.Sum(i,1,i,ss2)/ss2-A.Sum(i,1,i,ss1)/ss1;
40  BatchProcess:= True;
   ExcludePB.Position:= 0;
   ExcludePB.Max:= nH0rep+1;
   try
     for i:= 1 to nH0rep do begin
45       ExcludePB.StepIt;
       //include all genes
       for j:= 0 to high(UseGeneInd) do
         UseGeneInd[j]:= 1;
       //setup randomly permuted samples
50       RandomPerm(sampleperm);
       // bootstrap samples
       { for j:= 0 to ss1+ss2-1 do
         sampleperm[j]:= Ran0(ss1+ss2-1)+1; }
       for j:= 0 to ss1-1 do
55         if sampleperm[j]>ss1 then begin
           s:= Trunc(sampleperm[j])-ss1;
           for k:= 1 to lines do
             PermMat1[k,j+1]:= B[k,s]-ss1/(ss1+ss2)*MeanDiff[k];
           . end
60       else begin

```

```

s:= Trunc(sampleperm[j]);
for k:= 1 to lines do
  PermMat1[k,j+1]:= A[k,s]+ss2/(ss1+ss2)*MeanDiff[k];
end;
5 for j:= ss1 to ss1+ss2-1 do
  if sampleperm[j]>ss1 then begin
    s:= Trunc(sampleperm[j])-ss1;
    for k:= 1 to lines do
      PermMat2[k,j-ss1+1]:= B[k,s]-ss1/(ss1+ss2)*MeanDiff[k];
10    end
  else begin
    s:= Trunc(sampleperm[j]);
    for k:= 1 to lines do
      PermMat2[k,j-ss1+1]:= A[k,s]+ss2/(ss1+ss2)*MeanDiff[k];
15    end;
  if i=1 then begin
    PermMat1.StoreOnFile(1,1,100,ss1,'perm1.txt');
    PermMat2.StoreOnFile(1,1,100,ss2,'perm2.txt');
  end;
20 //calculate distance curve for this permutation
  for j:= 1 to nsteps do begin
    DiffClusterForm.FindDiffClusterButtonClick(H0Button);
    DiffClusterForm.DistButtonClick(H0Button);
25 RandDistCurves[i,j]:= StrToFloat(DiffClusterForm.DistOutput.Caption);
    if DiffClusterForm.AdjustType.ItemIndex <=2 then
      ClassificationForm.AdjustOptions.ItemIndex:=
        DiffClusterForm.AdjustType.ItemIndex;
    ClassificationForm.CrossvalidButtonClick(H0Button);
30 RandCV[i,j]:= StrToFloat(ClassificationForm.PCorrectOutput.Text);
    if testset then begin
      ClassCurves[i,j]:=
        (StrToFloat(ClassifyTestSets(Class1Box.Text,True,True)) +
          StrToFloat(ClassifyTestSets(Class2Box.Text,False,True)))/2;
35 if ClassCurves[i,j]=100 then
      ShowMessage('Perfect again:');
    end;
    OneEliminationStep;
  end;
40 end;
{ //calculate percentiles (min-max)
  RandDistCurves.Resize(nH0rep+2,nsteps);
  for j:= 1 to nsteps do begin
    RandDistCurves.MinMax(1,j,nH0rep,j,stepmin,stepmax);
45 RandDistCurves[nH0rep+1,j]:= stepmin;
    RandDistCurves[nH0rep+2,j]:= stepmax;
  end; }

finally
50 PermMat1.Free;
  PermMat2.Free;
  RandDistCurves.StoreOnFile(1, 1, nH0rep, nsteps, 'randdistcurves.txt');
  RandDistCurves.Free;
  RandCV.StoreOnFile(1, 1, nH0rep, nsteps, 'randCV.txt');
55 RandCV.Free;
  MeanDiff.Free;
  if testset then begin
    ClassCurves.StoreOnFile(1, 1, nH0rep, nsteps, 'classcurves.txt');
    ClassCurves.Free;
60 end;

```

```

ExcludePB.Position:= 0;
//include all genes
for i:= 0 to high(UseGeneInd) do
  UseGeneInd[i]:= 1;
5  BatchProcess:= False;
end;
end;

procedure TExcludeForm.RandomClusterButtonClick(Sender: TObject);
10 var nH0rep, i, j, size: integer;
    RandDist, RandClass: TVector;
    testset: boolean;
    indexarr: array of double;
    F: TextFile;
15 begin
    nH0rep:= Trunc(H0repInput.Value);
    size:= Trunc(DiffClusterForm.NumElemInput.Value);
    initprogress(ExcludePB, nH0rep);
    testset:= (FileExists(Class1Box.Text)) and
20      (FileExists(Class2Box.Text));
    RandDist:= TVector.Create(nH0rep);
    if testset then begin
      RandClass:= TVector.Create(nH0rep);
      if not Assigned(ClassificationForm) then
25        ClassificationForm:= TClassificationForm.Create(self);
    end;
    SetLength(indexarr, lines);
    for i:= 0 to lines-1 do
      indexarr[i]:= i+1;
30  BatchProcess:= True;
  try
    for i:= 1 to nH0rep do begin
      RandomPerm(indexarr);
      with DiffClusterForm do begin
35        OutputMemo.Clear;
        OutputMemo.Text:= IntToStr(Trunc(indexarr[0]));
        for j:= 2 to size do
          OutputMemo.Text:= OutputMemo.Text + ', ' +
            IntToStr(Trunc(indexarr[j]));
40        DistButtonClick(RandomClusterButton);
        RandDist[i]:= StrToFloat(DistOutput.Caption);
        if testset then begin
          RandClass[i]:=
45            (StrToFloat(ClassifyTestSets(Class1Box.Text, True, True)) +
              StrToFloat(ClassifyTestSets(Class2Box.Text, False, True)))/2;
        end;
      end;
      stepup(ExcludePB);
    end;
50  finally
    BatchProcess:= False;
    initprogress(ExcludePB, 1);
    AssignFile(F, 'randdist_class.txt');
    Rewrite(F);
55  if testset then begin
    Writeln(F, 'distance', chr(9), 'aveclass');
    for i:= 1 to nH0rep do
      writeln(F, RandDist[i], chr(9), RandClass[i]);
    CloseFile(F);
60  RandDist.Free;

```



```

    RandClass.Free;
end
else begin
    Writeln(F, 'distance');
5   for i:= 1 to nH0rep do
        writeln(F, RandDist[i]);
    CloseFile(F);
    RandDist.Free;
end;
10  end;
end;

procedure TExcludeForm.RunFromDiffClButtonClick(Sender: TObject);
var GeneList: TStringList;
15   i, j, nsteps, nelem, llength: integer;
    testset: boolean;
begin
    GeneList:= TStringList.Create;
    GeneList.CommaText:= DiffClusterForm.OutputMemo.Text;
20   llength:= GeneList.Count;
    nelem:= Trunc(DiffClusterForm.NumElemInput.Value);
    nsteps:= Trunc(llength/nelem);
    ExcludeResult.RowCount:= nsteps+1;
    testset:= (FileExists(Class1Box.Text)) and
25   (FileExists(Class2Box.Text));
    ExcludePB.Position:= 0;
    ExcludePB.max:= nsteps + 1;
    for i:= 1 to nsteps do begin
        try
30         ExcludePB.StepIt;
        ExcludePB.Update;
        BatchProcess:= True;
        with DiffClusterForm.OutputMemo do begin
            Clear;
35             Text:= GeneList[(i-1)*nelem];
            for j:= 1 to nelem-1 do
                Text:= Text + ', ' + GeneList[(i-1)*nelem + j];
            end;
            DiffClusterForm.DistButtonClick(self);
40         if not Assigned(ClassificationForm) then
            ClassificationForm:= TClassificationForm.Create(self);
            if DiffClusterForm.AdjustType.ItemIndex <=2 then
                ClassificationForm.AdjustOptions.ItemIndex:=
                    DiffClusterForm.AdjustType.ItemIndex;
45         ClassificationForm.CrossvalidButtonClick(self);
            ExcludeResult.Row:= i;
            ExcludeResult.CellAsInt[0,i]:= i;
            ExcludeResult.Cells[1,i]:= DiffClusterForm.OutputMemo.Text;
            ExcludeResult.Cells[2,i]:= ClassificationForm.PCorrectOutput.Text+'%';
50         ExcludeResult.Cells[3,i]:= DiffClusterForm.DistOutput.Caption;
            ExcludeResult.Cells[4,i]:=
                FloatToStrF(MinFreqInDiffcl*100,ffFixed,3,1)+'%';
            ExcludeResult.Cells[5,i]:=
                FloatToStrF(MaxFreqInDiffcl*100,ffFixed,3,1)+'%';
55         if testset then begin
            ExcludeResult.Cells[6,i]:=
                ClassifyTestSets(Class1Box.Text,True,False)+'%';
            ExcludeResult.Cells[7,i]:=
                ClassifyTestSets(Class2Box.Text,False,False)+'%';
60         end;
    end;

```

```

    finally
      BatchProcess:= False;
    end;
    end;
5   ExcludePB.Position:= 0;
    DiffClusterForm.OutputMemo.Text:= GeneList.CommaText;
    GeneList.Free;
    end;
10  end.

```

Example 2: Analysis on Microarray Expression Data from Colon Cancer Cell Lines

Two colon cancer cell lines were used in this experiment. HT29 cells represent advanced, highly aggressive colon tumors. They contain mutations in both the APC gene and p53 gene, two tumor suppressor genes that frequently mutate during colon tumorigenesis. HCT116 cells manifest less aggressive colon tumors and harbor functional p53 and APC. They are defective in DNA repair. The experiment was performed with three RNA samples (1 µg RNA each). Cy-3-dCTP (green) was used to label HCT116 cells while Cy-5-dCTP (red) was used for HT29 cells. Six independent replicates were obtained each for HT29 and HCT116 cell lines. In addition, the data from a separate experiment was used as the independent test set, which contained eight replicates for each cell line.

The analysis of differential expression of the two cell lines was carried out similarly as the computer simulation study described supra. The number of permutation was set at 300 in this analysis (in accordance with Procedure 2 supra), and the size of the subsets is $k=5$ (in accordance with Procedure 4 supra). The results from application of the three stopping rules (the associated probability distance, the test set classification rate, and the cross validation classification rate) are shown in Fig. 2. The estimates of the corresponding null-distributions are shown in Fig. 3.

Referring to Fig. 2, the left y axis represents the associated probability distance while the right y axis denotes the classification rate based on the independent test set (hence test set classification rate - "Class") and the

classification rate based on cross validation using selected gene set (hence cross validation classification rate - "CV"). The x axis denotes the number of subsets of genes with a predetermined size of 5. The dotted horizontal lines represent the level of the 99th percentile of the null-distributions of the corresponding measures (i.e., the associated probability distance, the test set classification rate, and the cross validation classification rate); they were estimated by generating 300 random permutation samples that mimic "no-difference" data in accordance with Procedure 2 supra. Using the 99th percentile of the null-distribution as the cutoff, the cross validation rate approach stops at the 57th subset and the distance-based criteria stops at 56th subset (referring to the black diamonds on the solid lines "CV" and "Dist" in Fig. 2). Whereas, the smoothed (via isotonic regression as discussed supra) test set classification rate drops below the cutoff much earlier, at the 12th subset (referring to the black diamond on the solid line "Class" in Fig. 2). However, when the 95th percentile was used, the stopping points for all three measures were at closer vicinity relative to one other. The extremely high variability of the test set classification rate may be responsible for such discrepancy, since the test set data was generated in a separate and earlier experiment.

Further comparison was carried out between the multivariate random search procedure of this invention and a univariate selection approach. The genes were sorted according to the values of the corresponding marginal *t*-statistics and the top $56 \times 5 = 280$ genes were selected, such that the number of selected genes was identical to that identified by the multivariate distance-based cutoff criterion as discussed above. It was observed that the resulting two groups of differentially expressed genes share only 94 genes (33%). The first gene that did not appear in the group selected using the univariate approach – Hs.2867, Interferon-alpha induced 11.5KD protein – appeared in the fourth subset G_4 of genes identified by the multivariate selection approach. Interestingly, another copy of the same gene did appear in both groups and that corresponding changes in the interferon pathway in the HT29 cell line are well

known. Therefore, identification of this gene as being differentially expressed was an accurate conclusion and, the multivariate search method of this invention was advantageously more sensitive compared to the univariate approach.

5 It is to be understood that the description, specific examples and data, while indicating exemplary embodiments, are given by way of illustration and are not intended to limit the present invention. Various changes and modifications within the present invention will become apparent to the skilled artisan from the discussion, disclosure and data contained herein, and thus are
10 considered part of the invention.

CLAIMS

1. A method for identifying a set of genes from a multiplicity of
5 genes whose expression levels at a first state and a second state are measured in
replicates using one or more nucleotide arrays, thereby generating a first
plurality of independent measurements of the expression levels for said first
state and a second plurality of independent measurements of the expression
levels for said second state, which method comprises the following sequential
10 steps:

(a) identifying a quality function capable of evaluating the
distinctiveness between the first plurality and the second plurality;

(b) forming a first predetermined number of permutations from the first
and the second pluralities, dividing said permutations into a first permuted
15 plurality and a second permuted plurality, corresponding in size, to said first
and second plurality, respectively, and identifying groups of genes the size of
which is a second predetermined number, wherein the values of the quality
function for the group of genes in said first permuted and second permuted
pluralities attain the maximum;

20 (c) determining, from said first and second permuted pluralities, the
top α^{th} percentile of the null distribution based on a quantitative characteristic
of said groups of genes;

(d) identifying, based on the first and second pluralities, a subset of
genes the size of which is said second predetermined number, wherein the
25 values of the quality function for said subset of genes in said first and second
pluralities attain the maximum;

(e) adding to the set of genes, said subset, if the value of said
quantitative characteristic associated with said subset exceeds said top α^{th}
percentile of the null distribution; and

(f) removing from the first and second pluralities, all measurements on said subset, if the maximum value of the quality function associated with said subset exceeds said top α^{th} percentile of the null distribution, and repeating steps (d)-(f) until no more measurements are left in the first and second pluralities or the value of said quantitative characteristic associated with the subset does not exceed said top α^{th} percentile of the null distribution.

2. The method of claim 1, wherein said states are selected from the group consisting of biological states, physiological states, pathological states, and prognostic states.

3. A method for identifying a set of genes from a multiplicity of genes whose expression levels in a first tissue and a second tissue are measured in replicates using one or more nucleotide arrays, thereby generating a first plurality of independent measurements of the expression levels for said first tissue and a second plurality of independent measurements of the expression levels for said second tissue, which method comprises:

(a) identifying a quality function capable of evaluating the distinctiveness between the first plurality and the second plurality;

(b) forming a first predetermined number of permutations from the first and the second pluralities, dividing said permutations into a first permuted plurality and a second permuted plurality, corresponding in size to said first and second plurality, respectively, and identifying groups of genes the size of which is a second predetermined number, wherein the values of the quality function for the group of genes in said first permuted and second permuted pluralities attain the maximum;

(c) determining, from said first and second permuted pluralities, the top α^{th} percentile of the null distribution based on a quantitative characteristic of said groups of genes;

(d) identifying, based on the first and second pluralities, a subset of genes the size of which is said second predetermined number, wherein the values of the quality function for said subset of genes in said first and second pluralities attain the maximum;

5 (e) adding to the set of genes, said subset, if the value of said quantitative characteristic associated with said subset exceeds said top α^{th} percentile of the null distribution; and

(f) removing from the first and second pluralities, all measurements on said subset, if the maximum value of the quality function associated with said
10 subset exceeds said top α^{th} percentile of the null distribution, and repeating steps (d)-(f) until no more measurements are left in the first and second pluralities or the value of said quantitative characteristic associated with the subset does not exceed said top α^{th} percentile of the null distribution.

4. The method of claim 3, wherein said tissues are selected from the
15 group consisting of normal lung tissues, cancer lung tissues, normal heart tissues, pathological heart tissues, normal and abnormal colon tissues, normal and abnormal renal tissues, normal and abnormal prostate tissues, and normal and abnormal breast tissues.

5. A method for identifying a set of genes from a multiplicity of
20 genes whose expression levels in a first type of cells and a second type of cells are measured in replicates using one or more nucleotide arrays, thereby generating a first plurality of independent measurements of the expression levels for said first type of cells and a second plurality of independent measurements of the expression levels for said second types of cells, which
25 method comprises:

(a) identifying a quality function capable of evaluating the distinctiveness between the first plurality and the second plurality;

(b) forming a first predetermined number of permutations from the first and the second pluralities, dividing said permutations into a first permuted plurality and a second permuted plurality, corresponding in size, to said first and second plurality, respectively, and identifying groups of genes the size of which is a second predetermined number, wherein the values of the quality function for the group of genes in said first permuted and second permuted pluralities attain the maximum;

(c) determining, from said first and second permuted pluralities, the top α^{th} percentile of the null distribution based on a quantitative characteristic of said groups of genes;

(d) identifying, based on the first and second pluralities, a subset of genes the size of which is said second predetermined number, wherein the values of the quality function for said subset of genes in said first and second pluralities attain the maximum;

(e) adding to the set of genes, said subset, if the value of said quantitative characteristic associated with said subset exceeds said top α^{th} percentile of the null distribution; and

(f) removing from the first and second pluralities, all measurements on said subset, if the maximum value of the quality function associated with said subset exceeds said top α^{th} percentile of the null distribution, and repeating steps (d)-(f) until no more measurements are left in the first and second pluralities or the value of said quantitative characteristic associated with the subset does not exceed said top α^{th} percentile of the null distribution.

6. The method of claim 5, wherein said types of cells are selected from the group consisting of normal lung cells, cancer lung cells, normal heart cells, pathological heart cells, normal and abnormal colon cells, normal and abnormal renal cells, normal and abnormal prostate cells, and normal and abnormal breast cells.

7. The method of claim 5, wherein said type of cells are selected from the group consisting of cultured cells and cells isolated from an organism.

8. The method of claim 1, 3, or 5, wherein said quality function is a probability distance function.

5 9. The method of claim 8, wherein said probability distance function is selected from the group consisting of the Mahalanobis distance and the Bhattacharya distance.

10. The method of claim 8, wherein the probability distance function is defined as:

10
$$N(\mu, \nu) = 2 \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\mu(x) d\nu(y) - \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\mu(x) d\mu(y) - \int_{\mathbb{R}^d} \int_{\mathbb{R}^d} L(x, y) d\nu(x) d\nu(y)$$
 where μ and ν are two probability measures defined on the Euclidean space, and $L(x, y)$ is a strictly negative definite kernel.

11. The method of claim 10, wherein the negative definite kernel is combined with the Euclidean distance between x and y to form a composite
15 kernel function.

12. The method of claim 1, 3, or 5, wherein the quantitative characteristic is selected from the group consisting of an associated probability distance, a test set classification rate, and a cross validation classification rate.

13. The method of claim 1, 3, or 5, wherein the formation of the
20 permutations further comprises:

(i) shifting the measurements in the first and second pluralities such that the marginal means thereof share the same true mean; and

(ii) randomly permuting the resulting shifted measurements thereby forming a null-distribution of permutations.

25 14. The method of claim 1, 3, or 5, wherein the identifying further comprises:

(i) calculating the values of the quality function for said subset of genes in said first and second pluralities thereby evaluating the distinctiveness of said first and second pluralities;

(ii) substituting a gene in said subset with one outside of said subset, thereby generating a new subset, and repeating step (i), keeping the new subset if the distinctiveness increases and the original subset if otherwise; and

(iii) repeating steps (i) and (ii) for a fourth predetermined number of times.

15 15. The method of claim 1, 3, or 5, wherein the identifying further comprises:

(i) randomly dividing the first and the second pluralities into v groups of an approximate equal size;

(ii) removing one of said v groups from said first and second pluralities and identifying, from the resulting reduced first and second pluralities, a subset of genes for which the value of said quality function attains the maximum; and

(iii) repeating step (ii) for each of said v groups thereby obtaining v subsets of genes.

20 16. The method of claim 1, 3, or 5, wherein the nucleotide arrays are selected from the group consisting of arrays having spotted thereon cDNA sequences and arrays having synthesized thereon oligonucleotides.

Fig. 1





Fig. 2





Fig. 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/07103

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : G01N 33/48

US CL : 702/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 702/19,20; 435/6,69.1;703/11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,331,396 B1 (SILVERMAN et al.) 18 December 2001(18.12.2001), see especially the abstract and section entitled SUMMARY OF THE INVENTION in columns 2-3.	1-16
Y	US 6,203,987 B1 (FRIEND et al.) 20 March 2001(20.03.2001), see especially the title, abstract, and the section entitled SUMMARY OF THE INVENTION in columns 2-4.	1-16
Y	US 6,303,301 B1 (MACK) 16 October 2001(16.10.2001), see especially the title, abstract, and the section entitled SUMMARY OF THE INVENTION in columns 1-4.	1-16
Y	US 6,221,600 B1 (MACLEOD et al.) 24 April 2001(24.04.2001), see especially the title, abstract, and the section entitled SUMMARY OF THE INVENTION in columns 4-7	1-16
Y	US 6,351,712 B1 (STOUGHTON et al.) 26 February 2002(26.02.2002), see especially the title and the section entitled SUMMARY OF THE INVENTION in columns 4-6.	1-16
Y	US 6,340,565 B1 (OLINER et al.) 22 January 2002(22.01.2002), see especially the title, abstract and the section entitled SUMMARY OF THE INVENTION in columns 1-3.	1-16
Y	US 6,160,105 A (CUNNINGHAM et al.) 12 December 2000(12.12.2000), see especially the title, abstract, and the section entitled SUMMARY OF THE INVENTION in columns 1-2.	1-16

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

14 June 2003 (14.06.2003)

Date of mailing of the international search report

03 JUL 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Felicia D. Robert for
Ardin Marschel

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

PCT/US03/07103

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,160,104 A (CUNNINGHAM et al.) 12 December 2000(12.12.2002), see especially the title, abstract, and the section entitled SUMMARY OF THE INVENTION in columns 1-3.	1-16

INTERNATIONAL SEARCH REPORT

PCT/US03/07103

Continuation of B. FIELDS SEARCHED Item 3:

WEST, CAS, EMBASE, MEDLINE, BIOSIS, BIOTECH ABS., WPI covering search terms: genes, set, expression, levels, state, array, microarray, nucleotide, measurements, quality, function, permutations, groups, profiles, characteristics, maximum, null, percentile, distribution, and cancer, renal, prostate, lung, normal, abnormal, and breast